Concepedia

Author

Marion Dahlke

Novartis (Switzerland)

Also Known As

Dahlke, Marion, M B Dahlke, M Dahlke, M. B. Dahlke, M. Dahlke, M.B. Dahlke, Marion Dahlke

57

Publications

732

Citations

15

H-Index

28

Concepts

All Affiliations

Novartis (Switzerland)Novartis (United States)Novartis (India)Novartis (United Kingdom)Azienda Ospedaliera S.Giuseppe Moscati
MD

About

Marion Dahlke is an author at Novartis (Switzerland) specializing in medicine, pharmacology, and hemodialysis.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

124

2

Health Sciences

1

1

31

3

Immunology

1

1

31

4

Nephrology

1

1

27

5

Nutrition

1

1

66

Marion Dahlke

×

18

Publications

663

Citations

15

H-Index

YearCitations

Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria

Régis Peffault de Latour, Alexander Röth, Austin Kulasekararaj,

New England Journal of Medicine

2024

119

A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure

Piotr Ponikowski, Veselin Mitrović, Mikhail Ruda,

European Heart Journal

2013

118

Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects

Sam Rebello, Sally Zhao, Sam Hariry,

European Journal of Clinical Pharmacology

2011

66

Renal Hemodynamic Effects of Serelaxin in Patients With Chronic Heart Failure

Adriaan A. Voors, Marion Dahlke, Sven Meyer,

Circulation Heart Failure

2014

48

Granulocyte transfusions and outcome of alloimmunized patients with gram‐negative sepsis

Marion Dahlke, M. A. Keashen, Jane Β. Alavi,

Transfusion

1982

36

Pharmacokinetics of serelaxin in patients with hepatic impairment: a single‐dose, open‐label, parallel group study

Zhanna Kobalava, S. V. Villevalde, Yu. V. Kotovskaya,

British Journal of Clinical Pharmacology

2014

32

Safety and tolerability of serelaxin, a recombinant human relaxin‐2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populations

Marion Dahlke, Dik Ng, Masayuki Yamaguchi,

The Journal of Clinical Pharmacology

2014

32

Phospholipid composition of blood plasma, erythrocytes, and "ghosts" in sickle cell disease.

Hans‐Peter Schwarz, Marion Dahlke, L. Dreisbach

Clinical Chemistry

1977

31

Pharmacokinetics of serelaxin in patients with severe renal impairment or end‐stage renal disease requiring hemodialysis: A single‐dose, open‐label, parallel‐group study

Marion Dahlke, Atef Halabi, Jasna Canadi,

The Journal of Clinical Pharmacology

2015

27

Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin–angiotensin system activity in obese hypertensive patients

Michael Boschmann, Jürg Nussberger, Stefan Engeli,

Journal of Hypertension

2012

23

Page 1